Helix BioPharma Presents New Data on CEACAM6-Targeted ADC Program at World ADC London Conference

Helix BioPharma Corp. presented new data on its CEACAM6-directed antibody-drug conjugate program at the 16th Annual World ADC London conference. The presentation, delivered by Director of ADC Discovery Jonathan Davis, PhD, focused on the development of next-generation ADCs targeting CEACAM6, a protein highly expressed in various epithelial cancers.

The conference presentation highlighted CEACAM6 as an attractive therapeutic target due to its elevated expression across multiple cancers, association with poor clinical outcomes, and limited presence in healthy tissues. Dr. Davis presented data supporting the tumor-selective binding profile of Helix’s proprietary anti-CEACAM6 VHH, a single-domain antibody fragment derived from camelid antibodies that demonstrated preferential binding to tumor-expressed CEACAM6.

This selective binding profile supports the development of ADCs designed to deliver potent therapeutic payloads directly to cancer cells while minimizing off-target effects. The approach builds on the clinical foundation established by Helix’s lead CEACAM6-targeted candidate, Tumor Defense Breaker L-DOS47, which has shown favorable safety and encouraging clinical activity in Phase I/II studies in non-small cell lung cancer.

‘CEACAM6 represents a compelling and underexploited target with broad potential across multiple hard-to-treat cancers,’ said Dr. Davis. ‘Our proprietary VHH-based targeting approach enables highly selective tumor binding, supporting the development of next-generation ADCs designed to maximize therapeutic impact while minimizing off-target effects.’

The presentation generated significant interest among conference participants, reflecting growing recognition of CEACAM6 as an important emerging target in oncology. A copy of the presentation is available on the company’s website at https://helixbiopharma.com/wp-content/uploads/2026/02/Unlocking-the-Potential-of-CEACAM6.pdf.

The World ADC London conference, now in its 16th year, is one of the leading global conferences dedicated to ADC research and development, bringing together more than 700 industry stakeholders from over 240 companies. The event provides a forum for scientific exchange and collaboration to advance next-generation ADC innovation and targeted cancer therapies. More information about the conference is available at https://worldadc-europe.com/.

The development of CEACAM6-targeted therapies represents an important advancement in oncology, particularly for cancers that have proven difficult to treat with existing therapies. The ability to selectively target tumors while sparing healthy tissues could lead to more effective treatments with fewer side effects, addressing a significant unmet need in cancer care.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Helix BioPharma Presents New Data on CEACAM6-Targeted ADC Program at World ADC London Conference.

The post Helix BioPharma Presents New Data on CEACAM6-Targeted ADC Program at World ADC London Conference appeared first on citybuzz.